{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:07:01Z","timestamp":1787242021888,"version":"build-2736575974"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.phrs.2019.02.002","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T06:53:17Z","timestamp":1549781597000},"page":"267-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro"],"prefix":"10.1016","volume":"142","author":[{"given":"Richard A.","family":"Slivicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali S.","family":"Mali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea G.","family":"Hohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2019.02.002_bib0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.neuropharm.2017.06.015","article-title":"The cannabinoid system and pain","volume":"124","author":"Woodhams","year":"2017","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.phrs.2019.02.002_bib0010","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.nurt.2009.08.002","article-title":"Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside","volume":"6","author":"Rahn","year":"2009","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.phrs.2019.02.002_bib0015","first-page":"1209","article-title":"Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain","volume":"284","author":"Adams","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.phrs.2019.02.002_bib0020","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjp.0705529","article-title":"Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells","volume":"140","author":"Zoratti","year":"2003","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2019.02.002_bib0025","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2)","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol. Rev."},{"issue":"9","key":"10.1016\/j.phrs.2019.02.002_bib0030","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/nn.2616","article-title":"Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system","volume":"13","author":"Schlosburg","year":"2010","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.phrs.2019.02.002_bib0035","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1124\/jpet.112.201426","article-title":"Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects","volume":"345","author":"Kinsey","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.02.002_bib0040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.phrs.2012.10.013","volume":"67","author":"Guindon","year":"2013","journal-title":"Pharmacol. Res."},{"issue":"20","key":"10.1016\/j.phrs.2019.02.002_bib0045","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.1523\/JNEUROSCI.0403-12.2012","article-title":"Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy","volume":"32","author":"Khasabova","year":"2012","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.phrs.2019.02.002_bib0050","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1007\/s00213-016-4277-y","article-title":"A comparison of novel, selective fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) or dual FAAH\/MAGL inhibitors to suppress acute and anticipatory nausea in rat models","volume":"233","author":"Parker","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.phrs.2019.02.002_bib0055","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2174\/187152709789824624","article-title":"The endocannabinoid system and the treatment of mood and anxiety disorders","volume":"8","author":"Hill","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"1","key":"10.1016\/j.phrs.2019.02.002_bib0060","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nm803","article-title":"Modulation of anxiety through blockade of anandamide hydrolysis","volume":"9","author":"Kathuria","year":"2003","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.02.002_bib0065","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1208\/s12248-009-9110-7","article-title":"Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice","volume":"11","author":"Schlosburg","year":"2009","journal-title":"AAPS J."},{"issue":"5216","key":"10.1016\/j.phrs.2019.02.002_bib0070","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1126\/science.7770779","article-title":"Chemical characterization of a family of brain lipids that induce sleep","volume":"268","author":"Cravatt","year":"1995","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.phrs.2019.02.002_bib0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00213-006-0689-4","article-title":"Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality","volume":"192","author":"Naidu","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.phrs.2019.02.002_bib0080","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neuropharm.2013.10.006","article-title":"Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB(1) and CB(2) receptors","volume":"77","author":"Desroches","year":"2014","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.phrs.2019.02.002_bib0085","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.pain.2012.04.020","volume":"153","author":"Huggins","year":"2012","journal-title":"Pain"},{"issue":"12","key":"10.1016\/j.phrs.2019.02.002_bib0090","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/pm\/pnx046","article-title":"The MOBILE Study\u2014a phase IIa enriched enrollment randomized withdrawal trial to assess the analgesic efficacy and safety of ASP8477, a fatty acid amide hydrolase inhibitor, in patients with peripheral neuropathic pain","volume":"18","author":"Bradford","year":"2017","journal-title":"Pain Med."},{"key":"10.1016\/j.phrs.2019.02.002_bib0095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.urology.2017.02.029","article-title":"Fatty acid amide hydrolase inhibitor treatment in men with chronic prostatitis\/chronic pelvic pain syndrome: an adaptive double-blind, randomized controlled trial","volume":"103","author":"Wagenlehner","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.phrs.2019.02.002_bib0100","doi-asserted-by":"crossref","first-page":"i2727","DOI":"10.1136\/bmj.i2727","article-title":"Lessons from the fatal French study BIA-10-2474","volume":"353","author":"Moore","year":"2016","journal-title":"BMJ"},{"issue":"6342","key":"10.1016\/j.phrs.2019.02.002_bib0105","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aaf7497","article-title":"Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474","volume":"356","author":"van Esbroeck","year":"2017","journal-title":"Science"},{"issue":"33","key":"10.1016\/j.phrs.2019.02.002_bib0110","doi-asserted-by":"crossref","first-page":"31163","DOI":"10.1074\/jbc.M101607200","article-title":"Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1","volume":"276","author":"Olah","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.02.002_bib0115","doi-asserted-by":"crossref","first-page":"33307","DOI":"10.1038\/srep33307","article-title":"Spatial distribution of the cannabinoid type 1 and capsaicin receptors may contribute to the complexity of their crosstalk","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.phrs.2019.02.002_bib0120","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.bjp.0704904","article-title":"Anandamide is a partial agonist at native vanilloid receptors in acutely isolated mouse trigeminal sensory neurons","volume":"137","author":"Roberts","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2019.02.002_bib0125","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916649192","article-title":"A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase","volume":"12","author":"Carey","year":"2016","journal-title":"Mol. Pain"},{"key":"10.1016\/j.phrs.2019.02.002_bib0130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.phrs.2016.04.020","article-title":"Broad impact of deleting endogenous cannabinoid hydrolyzing enzymes and the CB1 cannabinoid receptor on the endogenous cannabinoid-related lipidome in eight regions of the mouse brain","volume":"110","author":"Leishman","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.phrs.2019.02.002_bib0135","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1124\/jpet.118.252288","article-title":"Brain-permeant and -impermeant inhibitors of fatty acid amide hydrolase synergize with the opioid analgesic morphine to suppress chemotherapy-induced neuropathic nociception without enhancing effects of morphine on gastrointestinal transit","volume":"367","author":"Slivicki","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2019.02.002_bib0140","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.phrs.2011.07.001","article-title":"The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system","volume":"64","author":"Moreno-Sanz","year":"2011","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.phrs.2019.02.002_bib0145","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3959(83)90201-4","article-title":"Ethical guidelines for investigations of experimental pain in conscious animals","volume":"16","author":"Zimmermann","year":"1983","journal-title":"Pain"},{"issue":"10","key":"10.1016\/j.phrs.2019.02.002_bib0150","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.biopsych.2017.06.032","article-title":"Positive allosteric modulation of cannabinoid receptor type 1 suppresses pathological pain without producing tolerance or dependence","volume":"84","author":"Slivicki","year":"2017","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2019.02.002_bib0155","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1124\/mol.115.098483","article-title":"CB1 knockout mice unveil sustained CB2-mediated antiallodynic effects of the mixed CB1\/CB2 agonist CP55,940 in a mouse model of paclitaxel-induced neuropathic pain","volume":"88","author":"Deng","year":"2015","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2019.02.002_bib0160","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.biopsych.2014.04.009","article-title":"Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal","volume":"77","author":"Deng","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2019.02.002_bib0165","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1124\/jpet.117.241901","article-title":"Cannabinoid CB2 agonist GW405833 suppresses inflammatory and neuropathic pain through a CB1 mechanism that is independent of CB2 receptors in mice","volume":"362","author":"Li","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2019.02.002_bib0170","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/mol.118.113233","article-title":"The cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal","volume":"95","author":"Li","year":"2018","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2019.02.002_bib0175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/mol.117.109355","article-title":"Slowly signaling G protein-biased CB2 cannabinoid receptor agonist LY2828360 suppresses neuropathic pain with sustained efficacy and attenuates morphine tolerance and dependence","volume":"93","author":"Lin","year":"2018","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2019.02.002_bib0180","doi-asserted-by":"crossref","first-page":"e0147620","DOI":"10.1371\/journal.pone.0147620","article-title":"Impact of genetic reduction of NMNAT2 on chemotherapy-induced losses in cell viability in vitro and peripheral neuropathy in vivo","volume":"11","author":"Slivicki","year":"2016","journal-title":"PLOS One"},{"key":"10.1016\/j.phrs.2019.02.002_bib0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.phrs.2016.10.007","article-title":"Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems","volume":"114","author":"Deng","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.phrs.2019.02.002_bib0190","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/s41598-017-01062-2","article-title":"Inflammatory and neuropathic nociception is preserved in GPR55 knockout mice","volume":"7","author":"Carey","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2019.02.002_bib0195","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.neuropharm.2015.05.038","article-title":"Small molecule inhibitors of PSD95-nNOS protein-protein interactions as novel analgesics","volume":"97","author":"Lee","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2019.02.002_bib0200","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.neuropharm.2017.02.020","article-title":"Effects of paclitaxel on the development of neuropathy and affective behaviors in the mouse","volume":"117","author":"Toma","year":"2017","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.phrs.2019.02.002_bib0205","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/jpet.116.236182","article-title":"Palmitoylethanolamide reverses paclitaxel-induced allodynia in mice","volume":"359","author":"Donvito","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.02.002_bib0210","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/jpet.117.245704","article-title":"Monoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy","volume":"366","author":"Curry","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2019.02.002_bib0215","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bph.12439","article-title":"Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy","volume":"171","author":"Ward","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2019.02.002_bib0220","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1213\/ANE.0b013e3182283486","article-title":"Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice","volume":"113","author":"Ward","year":"2011","journal-title":"Anesth. Analg."},{"issue":"11","key":"10.1016\/j.phrs.2019.02.002_bib0225","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/2041-210X.12584","article-title":"BORIS: a free, versatile open-source event-logging software for video\/audio coding and live observations","volume":"7","author":"Friard","year":"2016","journal-title":"Methods Ecol. Evol."},{"issue":"18","key":"10.1016\/j.phrs.2019.02.002_bib0230","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"issue":"15","key":"10.1016\/j.phrs.2019.02.002_bib0235","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose-response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.phrs.2019.02.002_bib0240","doi-asserted-by":"crossref","DOI":"10.1177\/1744806918801224","article-title":"ZLc002, a putative small molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability","volume":"14","author":"Lee","year":"2018","journal-title":"Mol. Pain"},{"issue":"4","key":"10.1016\/j.phrs.2019.02.002_bib0245","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"2","key":"10.1016\/j.phrs.2019.02.002_bib0250","first-page":"93","article-title":"What is synergy?","volume":"41","author":"Berenbaum","year":"1989","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.phrs.2019.02.002_bib0255","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann. Appl. Biol."},{"issue":"6","key":"10.1016\/j.phrs.2019.02.002_bib0260","first-page":"285","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"Loewe","year":"1953","journal-title":"Arzneimittelforschung."},{"issue":"21","key":"10.1016\/j.phrs.2019.02.002_bib0265","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1111\/bph.13970","article-title":"Effects of centrally administered endocannabinoids and opioids on orofacial pain perception in rats","volume":"174","author":"Zubrzycki","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2019.02.002_bib0270","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jaim.2016.08.001","article-title":"Biochanin-A attenuates neuropathic pain in diabetic rats","volume":"7","author":"Chundi","year":"2016","journal-title":"J. Ayurveda Integr. Med."},{"issue":"3","key":"10.1016\/j.phrs.2019.02.002_bib0275","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1124\/jpet.109.155465","article-title":"Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain","volume":"330","author":"Kinsey","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.phrs.2019.02.002_bib0280","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jpain.2010.04.001","article-title":"Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms","volume":"11","author":"Kinsey","year":"2010","journal-title":"J. Pain"},{"issue":"1","key":"10.1016\/j.phrs.2019.02.002_bib0285","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1124\/jpet.107.119941","article-title":"The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3\u2032-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice","volume":"322","author":"Russo","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.02.002_bib0290","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/sj.bjp.0706699","article-title":"Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms","volume":"148","author":"Chang","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2019.02.002_bib0295","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1152\/jn.00692.2014","article-title":"Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy","volume":"113","author":"Uhelski","year":"2015","journal-title":"J. Neurophysiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.02.002_bib0300","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.phrs.2012.02.012","article-title":"Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions","volume":"65","author":"Sasso","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.02.002_bib0305","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1744-8069-10-27","article-title":"Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery","volume":"10","author":"Rahn","year":"2014","journal-title":"Mol. Pain"},{"issue":"2","key":"10.1016\/j.phrs.2019.02.002_bib0310","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/jpet.108.141994","article-title":"Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats","volume":"327","author":"Rahn","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2019.02.002_bib0315","article-title":"Comparison of brain permeant and impermeant inhibitors of fatty-acid amide hydrolase (FAAH) with the opioid analgesic morphine on the development and maintenance of paclitaxel-induced peripheral neuropathy","author":"Slivicki","year":"2017","journal-title":"Society for Neuroscience 2017, Washington, DC"},{"issue":"10","key":"10.1016\/j.phrs.2019.02.002_bib0320","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/nn.2632","article-title":"Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism","volume":"13","author":"Clapper","year":"2010","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.phrs.2019.02.002_bib0325","first-page":"1150","article-title":"CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol","volume":"285","author":"Cook","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1\u20132","key":"10.1016\/j.phrs.2019.02.002_bib0330","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0091-3057(01)00514-7","article-title":"Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine","volume":"69","author":"Lichtman","year":"2001","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"15","key":"10.1016\/j.phrs.2019.02.002_bib0335","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s00213-015-3907-0","article-title":"Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist","volume":"232","author":"Tai","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.phrs.2019.02.002_bib0340","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neuroscience.2013.04.034","article-title":"Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal","volume":"248","author":"Scavone","year":"2013","journal-title":"Neuroscience"},{"issue":"8\u20139","key":"10.1016\/j.phrs.2019.02.002_bib0345","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s007020070043","article-title":"Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice","volume":"107","author":"Darmani","year":"2000","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"1","key":"10.1016\/j.phrs.2019.02.002_bib0350","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/jpet.108.150136","article-title":"Endocannabinoid modulation of scratching response in an acute allergenic model: a new prospective neural therapeutic target for pruritus","volume":"329","author":"Schlosburg","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1\u20132","key":"10.1016\/j.phrs.2019.02.002_bib0355","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0091-3057(01)00647-5","article-title":"Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids","volume":"71","author":"Janoyan","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"3","key":"10.1016\/j.phrs.2019.02.002_bib0360","first-page":"1007","article-title":"Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice","volume":"298","author":"Lichtman","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2019.02.002_bib0365","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.05.029","article-title":"Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice","volume":"191","author":"Trexler","year":"2018","journal-title":"Drug Alcohol Depend."},{"issue":"16","key":"10.1016\/j.phrs.2019.02.002_bib0370","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.1021\/acs.jmedchem.6b00516","article-title":"Peripherally selective cannabinoid 1 receptor (CB1R) agonists for the treatment of neuropathic pain","volume":"59","author":"Seltzman","year":"2016","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2019.02.002_bib0375","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1124\/jpet.106.111385","article-title":"Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha","volume":"319","author":"LoVerme","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2019.02.002_bib0380","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1471-2407-12-92","article-title":"The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action","volume":"12","author":"Hamtiaux","year":"2012","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.phrs.2019.02.002_bib0385","doi-asserted-by":"crossref","first-page":"e26823","DOI":"10.1371\/journal.pone.0026823","article-title":"Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism","volume":"6","author":"Hamtiaux","year":"2011","journal-title":"PLOS One"},{"issue":"3","key":"10.1016\/j.phrs.2019.02.002_bib0390","doi-asserted-by":"crossref","first-page":"519","DOI":"10.18388\/abp.2017_1520","article-title":"Fatty acid amide hydrolase (FAAH) inhibitor PF-3845 reduces viability, migration and invasiveness of human colon adenocarcinoma Colo-205 cell line: an in vitro study","volume":"64","author":"Wasilewski","year":"2017","journal-title":"Acta Biochim. Pol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818312350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818312350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T12:03:06Z","timestamp":1556280186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818312350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":78,"alternative-id":["S1043661818312350"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.02.002","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}